Skip to content

Study · Observational study · 2025

9 results

C-REGS2-A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke.

Vosko MR, Sanak D, Do Y, Vatanagul JS, Roushdy T, Bornstein NM, Vester JC, Brainin M

International journal of stroke : official journal of the International Stroke Society24 Aug 2025Cited by 2 (Europe PMC)

PMID40851188 (opens in a new tab)PMCIDPMC12589672 (opens in a new tab)DOI10.1177/17474930251375439 (opens in a new tab)PepBankPUB-40851188
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In moderate ischemic stroke, Cerebrolysin was linked to better ordinal mRS at 90 days versus standard therapy, independently of prior thrombolysis.

    In plain wordsIn moderate stroke, Cerebrolysin was linked to better disability scores at 90 days versus standard therapy, independently of prior thrombolysis.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseOrdinal mRS at 90 days
    Study

    n: not reported in source

    Comparator
    Standard therapy alone
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml median · 10 days medianAs given in this study (human).

    Measurements

    MW
    0.6157
    Cerebrolysin versus standard therapy, ordinal mRS at 90 days
    Confidence interval (level not stated) for MW estimate for ordinal mRS
    0.591 to 0.6404
    Cerebrolysin versus standard therapy; 90 days
    P value for ordinal mRS at 90 days
    < 0.0001
    Cerebrolysin versus standard therapy; independently of prior thrombolysis

    Source sentences

    Summary
    Cerebrolysin was superior to standard therapy in the primary endpoint independently to prior thrombolysis (MW 0.6157; confidence interval (CI) 0.5910-0.6404; P < 0.0001)
    3 context sentences
    Summary · context
    The primary endpoint was ordinal analysis of the modified Rankin Scale (mRS) at 90 days after stroke onset.
    Summary · context
    Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8-15.
    Summary · context
    Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days.
  2. 02HumanObservational studyEfficacy outcome

    In moderate ischemic stroke, Cerebrolysin was linked to better ordinal mRS at day 21 versus standard therapy.

    In plain wordsIn moderate stroke, Cerebrolysin was linked to better disability scores at day 21 versus standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseOrdinal mRS at day 21
    Study

    n: not reported in source

    Comparator
    Standard therapy alone
    Analysis
    Secondary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml median · 10 days medianAs given in this study (human).

    Measurements

    MW
    0.6065
    Cerebrolysin versus standard therapy, ordinal mRS at day 21
    95% CI for MW
    0.5811 to 0.6319
    Cerebrolysin versus standard therapy, ordinal mRS at day 21
    P value
    < 0.0001
    Cerebrolysin versus standard therapy, ordinal mRS at day 21

    Source sentences

    Summary
    mRS at day 21 (MW 0.6065, 95% CI 0.5811-0.6319, P < 0.0001),
    2 context sentences
    Summary · context
    Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8-15.
    Summary · context
    Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days.
  3. 03HumanObservational studyEfficacy outcome

    In moderate ischemic stroke, Cerebrolysin was linked to better NIHSS at day 21 versus standard therapy.

    In plain wordsIn moderate stroke, Cerebrolysin was linked to better neurological scores at day 21 versus standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNIHSS at day 21
    Study

    n: not reported in source

    Comparator
    Standard therapy alone
    Analysis
    Secondary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml median · 10 days medianAs given in this study (human).

    Measurements

    MW
    0.5792
    Cerebrolysin versus standard therapy, NIHSS at day 21
    95% CI for MW
    0.5576 to 0.6008
    Cerebrolysin versus standard therapy, NIHSS at day 21
    P value
    < 0.0001
    Cerebrolysin versus standard therapy, NIHSS at day 21

    Source sentences

    Summary
    NIHSS at day 21 (MW 0.5792; 95% CI 0.5576-0.6008; P < 0.0001)
    2 context sentences
    Summary · context
    Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8-15.
    Summary · context
    Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days.
  4. 04HumanObservational studyEfficacy outcome

    In moderate ischemic stroke, Cerebrolysin was linked to better NIHSS at day 90 versus standard therapy.

    In plain wordsIn moderate stroke, Cerebrolysin was linked to better neurological scores at day 90 versus standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNIHSS at day 90
    Study

    n: not reported in source

    Comparator
    Standard therapy alone
    Analysis
    Secondary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml median · 10 days medianAs given in this study (human).

    Measurements

    MW
    0.5781
    Cerebrolysin versus standard therapy, NIHSS at day 90
    CI for MW (confidence level not stated)
    0.5561 to 0.6002
    Cerebrolysin versus standard therapy, NIHSS at day 90
    P value
    < 0.0001
    Cerebrolysin versus standard therapy, NIHSS at day 90

    Source sentences

    Summary
    and NIHSS at day 90 (MW 0.5781; CI 0.5561-0.6002; P < 0.0001).
    2 context sentences
    Summary · context
    Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8-15.
    Summary · context
    Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days.
  5. 05HumanObservational studyEfficacy outcome

    In moderate ischemic stroke, Cerebrolysin was linked to moderately more excellent recovery (mRS 0-1) at 90 days versus standard therapy.

    In plain wordsIn moderate stroke, Cerebrolysin was linked to moderately more excellent recovery at 90 days versus standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseExcellent recovery
    Study

    n: not reported in source

    Comparator
    Standard therapy alone
    Analysis
    Secondary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml median · 10 days medianAs given in this study (human).

    Source sentences

    Summary
    Additional pre-specified secondary endpoints (proportion of patients with excellent recovery and functional independence) showed moderate superiority for Cerebrolysin.
    3 context sentences
    Summary · context
    Secondary endpoints were the ordinal NIH Stroke Scale (NIHSS) at day 21 and 90 after stroke onset, the ordinal mRS at 21 days after IS, the proportion of patients with excellent recovery (mRS 0-1) as well as the proportion of patients with functional independence (mRS 0-2) at 90 days after stroke on…
    Summary · context
    Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8-15.
    Summary · context
    Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days.
  6. 06HumanObservational studyEfficacy outcome

    In moderate ischemic stroke, Cerebrolysin was linked to moderately more functional independence (mRS 0-2) at 90 days versus standard therapy.

    In plain wordsIn moderate stroke, Cerebrolysin was linked to moderately more functional independence at 90 days versus standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFunctional independence
    Study

    n: not reported in source

    Comparator
    Standard therapy alone
    Analysis
    Secondary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml median · 10 days medianAs given in this study (human).

    Source sentences

    Summary
    Additional pre-specified secondary endpoints (proportion of patients with excellent recovery and functional independence) showed moderate superiority for Cerebrolysin.
    3 context sentences
    Summary · context
    Secondary endpoints were the ordinal NIH Stroke Scale (NIHSS) at day 21 and 90 after stroke onset, the ordinal mRS at 21 days after IS, the proportion of patients with excellent recovery (mRS 0-1) as well as the proportion of patients with functional independence (mRS 0-2) at 90 days after stroke on…
    Summary · context
    Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8-15.
    Summary · context
    Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days.
  7. 07HumanObservational studyEfficacy outcome

    In moderate ischemic stroke, Cerebrolysin was linked to better ordinal MoCA at 90 days versus standard therapy in the target population.

    In plain wordsIn moderate stroke, Cerebrolysin was linked to better cognitive scores at 90 days versus standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseOrdinal MoCA
    Study

    n: not reported in source

    Comparator
    Standard therapy alone
    Analysis
    Secondary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml median · 10 days medianAs given in this study (human).

    Measurements

    MW
    0.553
    Cerebrolysin versus standard therapy, ordinal MoCA at 90 days, target population
    CI for MW (confidence level not stated)
    0.5282 to 0.5778
    Cerebrolysin versus standard therapy, ordinal MoCA at 90 days, target population
    P value
    < 0.0001
    Cerebrolysin versus standard therapy, ordinal MoCA at 90 days, target population

    Source sentences

    Summary
    The ordinal MoCA showed superiority for Cerebrolysin in the TP (MW 0.5530; CI 0.5282-0.5778; P < 0.0001) with more pronounced effects in the subgroup with cognitive impairments at baseline (Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) ⩾ 3.3).
    2 context sentences
    Summary · context
    Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8-15.
    Summary · context
    Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days.
  8. 08HumanObservational studyEfficacy outcome

    In moderate stroke with baseline cognitive impairment, Cerebrolysin was linked to more pronounced MoCA benefits versus standard therapy.

    In plain wordsIn stroke patients with existing cognitive impairment, Cerebrolysin was linked to more pronounced cognitive benefits versus standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseOrdinal MoCA in baseline cognitive impairment
    Study

    n: not reported in source

    Comparator
    Standard therapy alone
    Analysis
    Secondary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml median · 10 days medianAs given in this study (human).

    Source sentences

    Summary
    The ordinal MoCA showed superiority for Cerebrolysin in the TP (MW 0.5530; CI 0.5282-0.5778; P < 0.0001) with more pronounced effects in the subgroup with cognitive impairments at baseline (Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) ⩾ 3.3).
    2 context sentences
    Summary · context
    Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8-15.
    Summary · context
    Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days.
  9. 09HumanObservational studySafety outcome

    In moderate ischemic stroke, safety measures did not differ between Cerebrolysin and standard therapy.

    In plain wordsIn moderate stroke, safety measures did not differ between Cerebrolysin and standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeSafety measures
    Study

    n: not reported in source

    Comparator
    Standard therapy alone
    Outcome group
    Adverse events · Whole body
    Studied dose
    30 ml median · 10 days medianAs given in this study (human).

    Source sentences

    Summary
    No differences in safety measures were recorded.
    2 context sentences
    Summary · context
    Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8-15.
    Summary · context
    Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT03480698

Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

Ever Neuro Pharma GmbHn = 1,85124 Apr 2018 to 15 Jul 2024

Acute Ischemic Stroke

Trial pageClinicalTrials.govUpdated 25 Feb 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.